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Abstract
Sleep and circadian disruptions are commonly reported by patients with neurodegenerative diseases, suggesting these may
be an endophenotype of the disorders. Several mouse models of Huntington’s disease (HD) that recapitulate the disease
progression and motor dysfunction of HD also exhibit sleep and circadian rhythm disruption. Of these, the strongest effects
are observed in the transgenic models with multiple copies of mutant huntingtin gene. For developing treatments of the
human disease, knock-in (KI) models offer advantages of genetic precision of the insertion and control of mutation copy
number. Therefore, we assayed locomotor activity and immobility-defined sleep in a new model of HD with an expansion of
the KI repeats (Q175). We found evidence for gene dose- and age-dependent circadian disruption in the behavior of the
Q175 line. We did not see evidence for loss of cells or disruption of the molecular oscillator in the master pacemaker, the
suprachiasmatic nucleus (SCN). The combination of the precise genetic targeting in the Q175 model and the observed sleep
and circadian disruptions make it tractable to study the interaction of the underlying pathology of HD and the mechanisms
by which the disruptions occur.
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Introduction
Huntington’s disease (HD) is characterized by motor dysfunc-
tion and cognitive decline, and is caused by an autosomal
dominant expansion of CAG repeats in the Huntingtin (HTT) gene
[1]. HD patients present primarily with involuntary movements
(chorea) and loss of motor control. It is invariably fatal, age of
onset varies with the severity of the mutation, and there are no
significant treatment options to date [2,3]. In addition to the
motor dysfunction, HD patients often present with non-motor
symptoms that include cognitive dysfunction [4,5], affective
disorders [6–8] and sleep and circadian rhythm disruptions [9–
12], which can all precede the onset of chorea. As sleep and
circadian disruptions can themselves lead to similar non-motor
symptoms like mood disorders and cognitive dysfunction (e.g. [13–
16]), it is vital to parse out the relative contribution of sleep and
circadian rhythm disruptions.
To study the underlying mechanisms of sleep-wake disturbances
associated with HD, we first need to identify suitable animal
models that recapitulate as many symptom sets of HD as possible.
While there are numerous mouse models of HD, no single model
has yet been determined to be the ideal mirror of human HD [17].
Two examples of transgenic insertion HD mouse models are the
exon 1-fragment model (R6/2 [18]) and the stable 90Q-repeat
with full-length human HTT gene model (BACHD [19]).
Circadian deficits begin in the R6/2 line at 10 weeks, starting
with imprecise activity onset and progressing to a complete loss of
rhythms in activity [10,20]. The BACHD model exhibits a decline
in the power of circadian rhythms of activity at 3 months [20,21].
Of the current complement of HD mouse models, the knock-in of
140 CAG repeats into exon 1 of the mouse Htt gene (CAG140 KI
[22,23]) has considerable benefits as the genetically precise
insertion of the mutation into the Htt locus rules out position
and copy number effects that may affect the other transgenic
models. The age-related decline in circadian rhythms in the CAG
140 KI line was not distinguishable from the age-related decline
also observed in WT mice at 12 months of age, suggesting that the
effects of the targeted CAG repeats are subtle in the heterozygote
mutants [20]. A spontaneous expansion mutant that arose in this
line of mice, with over 175 CAG repeats (Q175), has motor and
cognitive deficits that have earlier onsets than the CAG140 line
[24], and thus may also exhibit sleep and circadian rhythm
disruption that can be detected before WT rhythms also decline.
We examined the spontaneous expansion Q175 model for sleep
and circadian rhythm disruptions over the course of 12 months of
age. We also examined the decline in motor function and the
impact of the mutation on circadian gene expression in the SCN.
Methods
Animals
The experimental protocols used in this study were approved by
the UCLA Animal Research Committee (ARC 2009-022), and all
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recommendations for animal use and welfare, as dictated by the
UCLA Division of Laboratory Animal Medicine and the
guidelines from the National Institutes of Health, were followed.
A line of mice with a spontaneous expansion of the CAG repeats
in the CAG140 KI line, the Q175 mutation, was obtained from
the CHDI colony of Q175 mice at the Jackson Laboratories (Bar
Harbor, Maine). The Q175 mice have previously been shown to
have around 188 CAG repeats [24]. We obtained an age-matched
cohort of male mice on the C57Bl6/J background that were wild-
type (WT), heterozygote (Het) and homozygote (Hom) for the
Q175 allele.
Monitoring of Locomotor Activity
Adult male mice (WT n=8, Q175 Het n=8, Q175 Hom n=8)
at 8 weeks of age were singly housed in cages containing wheels
(11.5 cm diameter, Mini Mitter, Bend, OR), and locomotor
activity was recorded as previously described [20,25,26]. Mice
were entrained to a 12:12 hr light:dark (LD) cycle for a minimum
of 2 weeks prior to collection of 10–14 days of data under LD
conditions, followed by 10–14 days in constant darkness (DD) to
obtain free-running activity. The behavioral response to a phase
delaying 10 min pulse of light (100 lux at cage level) at circadian
time (CT) 16 was measured as previously described [25,26].
Following these assays, the mice were entrained to 12:12 LD for a
minimum of 14 days. Mice were then exposed to 10–14 days of a
skeleton photoperiod of 1:11:1:11 LDLD to determine relative
entrainment to morning versus evening photic cues. The mice
were continuously housed in the same environment and subjected
to the same battery of lighting conditions and assays at each age
mark (3, 6, 9, and 12 months), and only removed from these
conditions to record motor function (at 6, 9 and 12 months as
described below) and behavioral sleep (at 9 and 12 months).
Wheel revolutions were recorded in 3 min bins, and 10 days of
data under each condition were averaged for analysis. Free-
running period (tau, t) was determined using the x2 periodogram
[27] and the power of the rhythm was determined by multiplying
the amplitude, Qp, by 100/n, where n=number of datapoints
examined (e.g. [28]) using the El Temps program (A. Diez-
Noguera, Barcelona, Spain). Activity amount was determined by
averaging 10 days of wheel revolutions (rev/hr). Activity duration
(alpha, a) was determined by the duration of activity over the
threshold of the mean using an average waveform of 10 days of
activity. Nocturnality was determined from the average percentage
of activity conducted during the dark. Precision was determined by
calculating the daily variation in onset from a best-fit regression
line drawn through 10 days of activity in both LD and DD
conditions using the Clocklab program (Actimetrics, Wilmette, IL).
Fragmentation was defined by bouts/day, where a bout was
Figure 1. Representative waveforms of wheel running activity from 3 to 12 months of age. Average waveforms from 10 days of wheel
running activity in LD are shown and standard errors across animals are indicated. The white/black bar on the top indicates the 12:12 hr light:dark
(LD) cycle, and gray shading in the waveforms indicates lights off. Sample sizes are the same as reported in Table 1. From left to right: WT, Q175 Het
and Hom. From top to bottom: 3, 6, 9 and 12 months of age.
doi:10.1371/journal.pone.0069993.g001
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determined as 21 consecutive minutes of activity (maxgap setting
of 21 min).
Motor Function Tests
We employed both the accelerating rotarod test [29] and
challenging beam test [30] to determine the progression of motor
dysfunction in the mice. All tests were performed at the light:dark
transition (ZT 11 to 12; one hour prior to lights-off) to minimize
effects of sleep deprivation.
At 6, 9 and 12 months, the mice were trained on the rotarod
(Ugo Basile, Varese, Italy) with 5 trials on the first day, as
previously described [29]. The accelerating rotarod went from 5 to
a maximum of 38 rpm and the maximum length of each trial was
600 sec. On the second day, mice were placed on the rotarod and
the latency to fall from the rotarod was recorded from 5 trials, and
averaged between trials.
We employed a modified version of the traditional beam
walking test, as described in detail by Fleming and colleagues [30].
The premise of this task, named the challenging beam test, is to
determine the ability of mice to cross a bridge of decreasing width,
with re-entry into the home cage as the motivating factor [30].
The beam narrows in 4 intervals from 33 mm .24 mm .18 mm
.6 mm, with each bridge spanning 253 mm in length. Mice at 9
and 12 months of age were trained on the beam for 5 consecutive
trials at ZT 11 on two consecutive days. During each trial, each
mouse was placed on the widest end of the beam and allowed to
cross with minimal handling by the experimenter. On the third
day, the mice were further challenged during testing by the
application of a metal grid (10610 mm spacing) overlaid onto the
bridge. A second experimenter was on hand to record the progress
of the animal using a hand held camcorder and five consecutive
trials were recorded. The videos were scored by two independent
observers blind to the experimental conditions for the time to cross
the beam and touch the home cage, the number of steps taken by
one designated limb, and the number of mis-steps (errors) made by
each mouse. We considered an error to have occured when more
Figure 2. Circadian deficits in locomotor activity in Q175 mutant mice at 9 months of age. A. Representative double plotted actograms of
wheel running activity from age-matched WT (left), Q175 Het (middle) and Q175 Hom (right) mice under 12:12 light:dark (LD) and constant darkness
(DD) are shown. The white/black bars on top indicate the LD cycle, and gray shading indicates darkness. Successive days of activity are plotted from
top to bottom. B. Chi-square (x2) periodograms of 10 days of activity in DD are shown from the three genotypes at 9 months, with the peak of the
periodogram indicating the free-running period of each mouse. Power (%V) refers to the normalized amplitude of the periodogram. The intersecting
diagonal line indicates significance to P,0.05.
doi:10.1371/journal.pone.0069993.g002
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Table 1. Circadian parameters of activity in LD and DD in WT, Q175 Het and Hom mice from 3 months to 12 months of age.
3 months old WT Q175 Het Q175 Hom One way ANOVA
n=8 n=8 n=8 dof F P
LD Nocturnality 97.560.7 97.560.9 94.861.5 2,23 H= 2.82 0.244
Power (%V) 68.961.9 71.462.6 68.764.4 0.23 0.794
Activity (rev/hr) 1239.2675.5 1210.3672.7 1150.3690.7 H= 0.74 0.692
Alpha, a (min) 612.9623.4 550.9619.0 598.3628.5 1.83 0.185
Fragmentation (bouts/day) 3.760.3 3.660.3 3.960.3 0.19 0.831
Precision (min) 28.161.6 211.662.4 215.666.3 H= 1.10 0.578
DD Tau, t (hr) 23.6260.09 23.8260.04 23.6260.08 2.32 0.123
Power (%) 56.562.8 67.762.1 65.963.0 5.17 0.015
Activity (rev/hr) 1055.6693.2 1166.0672.4 1039.7681.3 0.69 0.512
Alpha, a (min) 496.6619.8 497.4619.6 524.4612.5 0.81 0.460
Fragmentation (bouts/day) 5.060.3 4.460.3 4.960.3 1.19 0.323
Precision (min) 214.362.4 213.162.5 215.962.5 0.33 0.722
6 months old WT Q175 Het Q175 Hom
LD Nocturnality (%A in dark) 97.360.6 96.661.1 95.160.8 2,23 1.65 0.216
Power (%V) 63.363.8 58.964.9 61.565.3 0.22 0.805
Activity (rev/hr) 894.6672.2 766.5675.9 748.6671.1 1.19 0.325
Alpha, a (min) 544.2625.9 465.3629.6 529.7623.9 2.49 0.107
Fragmentation (bouts/day) 4.460.4 4.560.3 4.260.5 0.14 0.871
Precision (min) 27.261.5 213.262.3 210.662.2 H= 4.37 0.113
DD Tau, t (hr) 23.6460.08 23.7660.05 23.7060.09 0.61 0.552
Power (%) 46.965.3 51.464.4 54.766.5 H= 1.745 0.418
Activity (rev/hr) 748.96109.3 677.1661.5 636.3677.5 0.45 0.645
Alpha, a (min) 467.3624.4 453.9628.7 517.9623.7 1.73 0.201
Fragmentation (bouts/day) 6.060.5 5.060.3 4.660.6 2.09 0.148
Precision (min) 216.862.5 216.662.9 214.561.5 0.29 0.750
9 months old WT Q175 Het Q175 Hom
LD Nocturnality 95.360.9 94.161.1 91.063.8 2,22 H= 0.58 0.747
Power (%V) 50.965.2 41.263.8 22.062.8* H= 14.03 ,0.001
Activity (rev/hr) 651.56119.7 363.7650.0 98.2627.1* H= 15.77 ,0.001
Alpha, a (min) 529.9625.2 423.6647.8 462.3632.9 2.53 0.105
Fragmentation (bouts/day) 5.660.7 6.460.4 4.860.4 2.24 0.133
Precision (min) 215.862.3 217.263.1 2122.9625.5*‘ H= 14.76 ,0.001
DD Tau, t (hr) 23.860.1 23.860.1 23.960.1 0.39 0.686
Power (%) 38.665.7 30.163.8 17.961.7*‘ H= 10.28 0.006
Activity (rev/hr) 681.76115.5 334.6671.3 61.9611.7* H= 14.42 ,0.001
Alpha, a (min) 609.3647.6 523.1632.2 496.9662.1 1.49 0.249
Fragmentation (bouts/day) 6.160.7 6.960.4 4.360.2*‘ 8.45 0.002
Precision (min) 218.166.9 216.863.5 254.7610.2*‘ 9.38 0.001
12 months old WT Q175 Het Q175 Hom
LD Nocturnality 94.462.2 85.769.7 76.165.4*‘ 2,21 H= 9.47 0.009
Power (%V) 45.264.7 36.762.0 16.261.2*‘ 27.12 ,0.001
Activity (rev/hr) 554.3678.2 434.6681.0 26.465.9*‘ H= 14.86 ,0.001
Alpha, a (min) 635.1622.7 595.1682.4 516.1665.9 H= 1.99 0.368
Fragmentation (bouts/day) 5.760.5 6.960.5 4.360.6* 5.10 0.017
Precision (min) 216.363.5 225.861.7 2156.3631.9* H= 15.56 ,0.001
DD Tau, t (hr) 23.960.1 24.060.1 23.760.2 3.34 0.188
Power (%) 36.264.9 30.863.4 13.860.6*‘ H= 15.21 ,0.001
Activity (rev/hr) 562.1688.1 333.6663.6 17.363.3*‘ H= 16.68 ,0.001
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than half of the foot in question dipped below the grid. Time to
cross, number of steps, and number of errors were averaged across
the 5 trials per mouse to give the final reported values.
Video Measurement of Immobility-defined Sleep
Mice were habituated to see-through plastic cages containing
bedding, but without the addition of nesting material, for a
minimum of 3 days prior to video recording of behavior. Mice
were housed on a 12:12 LD cycle in keeping with their previous
housing conditions at 9 and 12 months of age. A side-on view of
each cage was obtained, with minimal occlusion by the food bin or
water bottle, both of which were top-mounted. Video capture was
accomplished using surveillance cameras with visible light filters
(Gadspot Inc., City of Industry, CA) connected to the video-
capture card (Adlink Technology Inc., Irvine, CA) on a Dell
Optiplex computer system. The AnyMaze software (Stoelting Co.,
Wood Dale, IL) was used to track the animals as described by
Fisher and colleagues [31], who found 99% correlation between
immobility-defined and EEG-defined sleep using an immobility
detection threshold set to 95% of the area of the animal immobile
for 40 seconds. Immobility-defined sleep in this study is thus
defined as 95% immobility recorded in an animal for a minimum
of 40 seconds. Continuous recording and tracking of the mice
under a 12:12 LD cycle was performed for a minimum of 3 days,
with randomized visits (1/day) by the experimenter to confirm
mouse health and video recording. We used data collected from
days 2 and 3 for further analysis. Immobility-defined sleep data
were exported in 1 min bins, and total sleep was determined by
summing the duration of sleep in the day (ZT 0–12) or night (ZT
12–24). Number of sleep bouts was determined using Clocklab at
the resolution of 1 min bins of Anymaze data (minimum of 40 sec
sleep per bin). Average bout duration (number of consecutive bins
with at least 40 sec of sleep per bin) was determined within day or
night. An average waveform of hourly sleep from both days was
produced per genotype per age group for the purpose of graphical
display. To address concerns that sleep measurements may be
over- or under-estimated in Q175 mutants, we analyzed the data
at 90 and 97% immobility, which have previously been correlated
by Fisher and colleagues [31] to simultaneous EEG recordings as
over-estimating sleep by 6 min per hour and under-estimating
sleep by 6 min per hour respectively. In our hands, these altered
thresholds changed the amount of sleep measured, but did not
change the overall findings (Text S1, Fig. S1 and Table S1).
Histology and Immunohistochemistry (IHC)
To determine cell counts and the expression of a core circadian
gene, we perfused 13 month old WT, Q175 Het and Hom mice at
either ZT 2 (2 hours after lights on; PER2 trough in SCN) or ZT
14 (2 hours after lights off; PER2 peak in SCN). Coronal sections
(20 mm) were cut, and the sections containing the SCN were
analyzed. Alternate sections of SCN were chosen for either Nissl
staining to determine cell counts or IHC with an antibody against
PER2 to determine the peak/trough of the molecular oscillator.
Neuronal cell bodies through the middle of the rostro-caudal
axis of the SCN were identified using Nissl stain (0.1% Cresyl
Violet). Sections through the SCN were photographed at 10X
magnification, and counts of cell bodies within a defined area were
determined by averaging the numbers from two investigators blind
to the conditions. The surface area of the SCN and the lateral
ventricles were determined using Axiovision (Carl Zeiss).
IHC staining for PER2 using free-floating sections was
performed as previously described [20]. Coronal brain sections
through the middle of the rostro-caudal axis of the SCN were
chosen for IHC using affinity-purified goat polyclonal antibody
raised against a peptide mapping to the N-terminal of mouse
PER2 (1:400; SC-7729; Santa Cruz Antibodies, Santa Cruz, CA).
To detect PER2 staining, avidin-biotin complex detection was
applied using the Vectastain ABC kit (Vector Laboratories,
Table 1. Cont.
3 months old WT Q175 Het Q175 Hom One way ANOVA
n=8 n=8 n=8 dof F P
Alpha, a (min) 604.1638.9 529.6622.0 183.7644.2*‘ H= 15.84 ,0.001
Fragmentation (bouts/day) 6.260.6 7.460.6 3.760.3*‘ 16.34 ,0.001
Precision (min) 225.362.2 216.262.5 2158.0647.2* H= 16.33 ,0.001
Parameters were analyzed using one-way ANOVA, and the F and P statistics are reported for genotype comparisons within each age group. H values are reported from
ANOVA on ranks comparisons in the event of failed normality or equal variance tests. * indicates that post hoc Bonferroni’s t-tests detected significant differences
compared to WT, and ‘ indicates significant differences were detected between Het and Hom groups.
doi:10.1371/journal.pone.0069993.t001
Table 2. Two way repeated measures ANOVA were used to
determine the effects of age and genotype in the same cohort
of mice from 3 to 12 months, and we report the F and P
statistics for the comparisons reported in Fig. 4 and 5 in this
table.
Two way repeated measures ANOVA
Age Genotype Interactions
F P F P F P
LD Nocturnality 6.01 0.001 1.52 0.242 1.74 0.126
Power (%V) 110.65 ,0.001 8.06 0.002 8.04 ,0.001
Activity (rev/hr) 141.72 ,0.001 11.26 ,0.001 4.79 ,0.001
Alpha, a (min) 7.44 ,0.001 3.72 0.041 0.89 0.511
Fragmentation (bouts/day) 22.15 ,0.001 3.19 0.062 3.58 0.004
Precision (min) 5.52 0.002 6.24 0.007 2.60 0.026
DD Tau, t (hr) 4.61 0.006 0.83 0.451 1.13 0.355
Power (%) 76.03 ,0.001 2.17 0.139 6.51 ,0.001
Activity (rev/hr) 77.04 ,0.001 13.99 ,0.001 4.96 ,0.001
Alpha, a (min) 4.93 0.004 12.06 ,0.001 12.19 ,0.001
Fragmentation (bouts/day) 5.86 0.001 9.21 0.001 7.95 ,0.001
Precision (min) 8.15 ,0.001 11.60 ,0.001 6.69 ,0.001
Sample sizes are as reported in Table 1.
doi:10.1371/journal.pone.0069993.t002
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Burlingame, CA) and incubation with 3-39-diaminobenzidine
tetrahydrochloride and 8% nickel chloride. Images were captured
with AxioVision camera systems (Carl Zeiss, Thornwood, NY).
Antibody specificity was confirmed with no-primary antibody and
blocking peptide control sections. To determine the number of
PER2-positive (PER2+) cells, photographs were taken at 40X
magnification, and cell counts were averaged between the
numbers determined by two investigators blind to the conditions.
Statistical Analysis
For comparison of WT, Q175 Het and Hom locomotor activity
and sleep parameters that passed normality and equal variance
tests within each age group, we applied one way analysis of
variance (ANOVA) for which we report the F statistic, and
deemed differences as significant if P,0.05. For any parameter
that failed either normality or equal variance tests, ANOVA on
ranks was applied and H values reported. To compare the effects
of gene dosage and age, we applied two way repeated measures
ANOVA. Post hoc Bonferroni’s t-test pairwise comparisons were
applied in the event of significant effects of genotype or age. In the
instance of failed normality or equality, Dunn’s method was used
instead. Values are reported as mean 6 standard error of the
mean (SEM).
Results
Q175 Mutant Mice Show Age- and Gene Dosage-related
Decline in Circadian Rhythms of Wheel Running Activity
We assayed an age-matched cohort of mice to determine the
impact of the Q175 mutation on circadian locomotor activity from
3 to 12 months of age. Young adult (3 months and 6 months)
Q175 mutant mice were not significantly different from their WT
counterparts, showing equally consolidated and precise rhythms in
activity that were nocturnal in nature under 12:12 light dark (LD)
conditions (Tables 1, 2). However, as the mice aged, the strength
of the rhythm (power) declined sharply in the Q175 Hom mice,
Figure 3. Circadian deficits in locomotor activity in Q175 mutant mice at 12 months of age. A. Representative double plotted actograms
of wheel running activity from age-matched WT (left), Q175 Het (middle) and Q175 Hom (right) mice under 12:12 light:dark (LD) and constant
darkness (DD) are shown. The white/black bars on top indicate the LD cycle, and gray shading indicates darkness. Successive days of activity are
plotted from top to bottom. B. Chi-square (x2) periodograms of 10 days of activity in DD are shown from the three genotypes at 12 months, with the
peak of the periodogram indicating the free-running period of each mouse. Power (%V) refers to the normalized amplitude of the periodogram. The
intersecting diagonal line indicates significance to P,0.05.
doi:10.1371/journal.pone.0069993.g003
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and by 9 months, circadian dysfunction was apparent (Fig. 1, 2).
This was characterized by a decrease in the precision and amount
of activity under both LD and constant darkness (DD) conditions
(Fig. 2A), along with greatly reduced power of free running
rhythms in DD (Fig. 2B). The age progression of circadian deficits
continued at 12 months (Fig. 3), albeit without a change in the
free-running period of the mutants (Fig. 4A). The power of the
free-running rhythm in DD decreased (Fig. 4B) and precision of
cycle-to-cycle onset worsened (Fig. 4C) as the Q175 Hom mice
aged from 9 to 12 months. The amount of activity in the Hom
mice remained low starting at 9 months and did not decline
further (Fig. 4D). Similar genotype- and age-dependent deficits
were observed under LD conditions, where the Q175 Hom mice
were less nocturnal (Fig. 5A), had lower power rhythms (Fig. 5B)
that were less precise (Fig. 5C) and an overall decline in activity
amount (Fig. 5D).
The reduced nocturnality of the Q175 Hom mice suggests
deficits in the light response, which we tested by exposing the mice
to discrete pulses of light to induce phase shifts in their free-
running rhythms. The light-induced phase delay increased in
magnitude in Q175 Hom mice, beginning at 9 months and
increasing further at 12 months compared to WT and Het mice
(Table 3). Housing mice under a skeleton photoperiod also
revealed deficits in the temporal patterning of activity that began
at 6 months in the Q175 Hom mice (Table 4).
We conclude from these wheel running assays that the Q175
Hom mutants show a rapid decline of rhythms in locomotor
activity from 9 months of age, with poor precision and abnormal
temporal patterning of activity. The Q175 Het mutants also
exhibit an age-related decline in the power of activity rhythms, but
to a lesser degree than the Hom mutants, suggesting an effect of
gene dosage.
Motor Function Declines with Age in Q175 Mutant Mice
We wished to determine if the Q175 line recapitulated the HD-
like symptoms observed in its preceding line, the CAG140 knock-
in model. As such, we performed two motor function tests
previously found robust enough to detect motor deficits in mouse
models of neurodegeneration: the accelerating rotarod test (e.g.
[28]) and a modified version of the beam walking test: the
challenging beam test [29].
At 6 months of age, we assayed our cohort of WT, Q175 Het
and Hom mice on the accelerating rotarod test, but found no
significant effect of genotype on motor function as determined by
latency to fall from the rotarod (F2,22 = 0.88, P=0.430). Somewhat
surprisingly, at 9 months, the Q175 Het and Hom mutants
showed a trend towards better performance on the test than the
WT controls (F2,22 = 2.935, P=0.076), but this paradoxical finding
was reversed by 12 months, where there was a gene dose-
dependent decline in motor function (Fig. 6A; F2,22 = 11.557,
P,0.001) with post hoc comparisons revealing that Het mice
performed worse than WT (t=2.419, P=0.025) and Hom mice
performed worse than both age-matched Het and WT mice (vs
Het t=2.225, P=0.0378; vs WT t=4.806, P=0.017).
Figure 4. Age-related decline in circadian rhythms of locomotor activity in Q175 mutants under DD conditions. A. Free-running
period (tau) is no different between the three genotypes. B. Power, as measured by the X2 periodogram, declines dramatically in Q175 Hom mutants
at 9 months. C. The cycle-to-cycle activity onset is less precise in Q175 Hom mutants from 9 months. D. The amount of activity (wheel revolutions per
hour, rev/hr) plummets in Q175 Hom mutants at 9 months. * indicates significance to P,0.05 in post hoc pairwise comparisons with WT within each
age group after the two way ANOVA revealed an effect of genotype. Effect of age within each genotype is indicated with #. F and P statistics are
reported in Table 2.
doi:10.1371/journal.pone.0069993.g004
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We employed the challenging beam test as a parallel test of the
motor coordination at 9 months. We found clear motor deficits in
the ability of Q175 Hom mice to cross the challenging beam at
both 9 and 12 months. The Q175 Hom mice took longer to cross
the beam at 9 and 12 months (Fig. 6B; 9 months F2,22 = 3.85,
P=0.039; 12 months F2,18 = 6.91, P=0.007). The number of
errors made by each Hom mouse were also considerably greater
than those made by WT and Q175 Het mice at the same age
(Fig. 6C; 9 months F2,22 = 13.569, P,0.001; 12 months
F2,18 = 17.794, P,0.001). In the Q175 Hom group at 12 months,
4 of 8 mice failed to cross the beam successfully, and were not
included further in the analysis.
The deterioration in challenging beam performance with age
was tested using two way ANOVA, which did not reveal a
significant effect of age on the time to cross the challenging beam
(age F1,41 = 3.341, P=0.076; genotype F2,41 = 10.761, P,0.001).
Figure 5. Age-related decline in rhythms of locomotor activity in Q175 mutants in LD conditions. A. The percentage of activity at night
(nocturnality) declines at 9 months in Q175 Hom mutants. B. Power, as measured by the x2 periodogram, declines dramatically in Q175 Hom mutants
at 9 months. C. The cycle-to-cycle activity onset is less precise in Q175 Hom mutants from 9 months. D. The amount of activity (wheel revolutions per
hour, rev/hr) declines sharply in Q175 Hom mutants at 9 months. * indicates significance to P,0.05 in post hoc pairwise comparisons with WT within
each age group after the two way ANOVA revealed an effect of genotype. Effect of age within each genotype is indicated with #. F and P statistics
are reported in Table 2.
doi:10.1371/journal.pone.0069993.g005
Table 3. Increased phase delay in response to a brief pulse of






3 months 11365 11866 11964
6 months 12065 11164 10366
9 months 11062 10362 120612
12 months 11965 10462 213624*‘
Data were analyzed using one way ANOVA within an age group. * indicates that
post hoc Bonferroni’s t-tests detected significant differences compared to WT,
and ‘ indicates significant differences were detected between Het and Hom
groups.
doi:10.1371/journal.pone.0069993.t003
Table 4. Reduced nocturnality of Q175 Hom mice revealed
by skeleton photoperiod.
WT Q175 Het Q175 Hom
n=8 n=7 n=8
Activity in subjective night
(%)
3 months 93.261.5 96.661.1 93.761.9
6 months 96.262.7 95.761.0 87.761.7*
9 months 75.863.3 79.567.4 79.864.1
12 months 89.362.0 95.461.7 69.667.1*
Data were analyzed using one way ANOVA within an age group. * indicates that
post hoc Bonferroni’s t-tests detected significant differences compared to WT.
doi:10.1371/journal.pone.0069993.t004
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On the other hand, the number of errors made while crossing the
beam was both age- and genotype-dependent (age F1,41 = 31.575,
P,0.001; genotype F2,41 = 32.741, P,0.001).
We can thus confirm that the Q175 Hom mice showed a
decline in motor performance at 9 months as revealed by the
challenging beam test, and that both Q175 Het and Hom mice
showed deficits compared to age-matched WT controls on the
accelerating rotarod test at 12 months.
Sleep Analysis by Video Tracking Reveals Deficits in
Temporal Patterning of Activity in Q175 Mutant Mice
We used video recording to measure sleep as defined by time
spent immobile, in combination with automated mouse tracking
analysis software. Average waveforms of hourly immobility-
defined sleep clearly show a change in the distribution of sleep
in the Q175 Hom mice at both 9 (Fig. 7A top) and 12 months
(Fig. 7A bottom). As nocturnal creatures, mice typically spend
majority of the daylight hours inactive, and the reduction in
nocturnality that we previously observed of Q175 Hom mutants
using wheel running activity is replicated in these video
measurements of freely behaving mice.
At 9 months, the Q175 Hom mutants spent less time in sleep
during the day than WT and Q175 Het mice (Fig. 7B top;
F2,22 = 8.85, P=0.002), although nighttime sleep did not vary
across the genotypes (F2,22 = 0.38, P=0.686). Similarly, at 12
months, the Q175 Hom mutants spent less time in sleep during the
day than age-matched WT and Q175 Het mice (Fig. 7B bottom;
F2,22 = 11.42, P,0.001), with no significant effect of genotype
during the night (F2,22 = 1.63, P=0.222). An effect of age was
confirmed by two way ANOVA comparing daytime sleep across
both ages of all three genotypes (F2,45 = 8.12, P=0.007) in addition
to an effect of genotype (F2,45 = 1.13, P,0.001). Post hoc pairwise
comparisons confirmed a significant difference between WT vs.
Q175 Hom (t15 = 4.98, P=0.025) and Q175 Het vs. Hom
(t14 = 5.75, P=0.017) in total daytime sleep duration.
To examine sleep quality in the Q175 model, fragmentation
analysis was performed to determine the number of sleep bouts
during both day and night, and the average duration of each bout
of sleep. At 9 months, there was no significant difference in the
number of daytime sleep bouts (Fig. 7C top, F2,22 = 1.78,
P=0.190). However, at 12 months of age, increased fragmentation
becomes apparent (Fig. 7C bottom, F2,22 = 5.33, P=0.014),
where the Q175 Hom mice have significantly more daytime sleep
bouts than WT mice (t15 = 3.25, P=0.012). Duration of the
average daytime sleep bout is selectively affected in Q175 mice at
both 9 months (Fig. 7D top, F2,22 = 4.99, P=0.020) and 12
months (Fig. 7D bottom, Fig. S2, F2,22 = 7.90, P=0.003).
The impact of the Q175 mutation appears to have a selective
effect on daytime sleep in the Hom mutants, with a specific
reduction of the amount of time spent asleep in the day, as well as
increased fragmentation of already reduced sleep.
Unaltered Nissl+and PER2+Cells in the SCN of Q175
Mutant Mice
The pathophysiology of HD is neurodegeneration followed by
neuronal cell death in vulnerable cell populations like the striatum.
The CAG140 KI line exhibited loss of striatal neurons as the
disease progressed [32,33]. Striatal volume was found to be
reduced in the Q175 Het and Hom mutant mice from 4 months
[34]. We examined the SCN to ascertain the impact of the Q175
mutation on the neuronal cell counts in WT, Het and Hom mice.
There were similar Nissl+cell counts in the SCN of all three
genotypes (Fig. 8A, 8B; F2,22 = 0.105, P=0.901). The size of the
SCN was not different amongst the three groups (F2,19 = 0.053,
P=0.949). Examination of the lateral ventricles suggested that the
Q175 Hom mice showed signs of brain volume loss (ANOVA
H19 = 6.069, P=0.048; post hoc comparison WT vs Hom
Q=2.409, P,0.05), in keeping with previous findings [34].
To determine the impact of the Q175 mutation on the
molecular oscillator in the SCN, we examined the core circadian
gene, PER2, at its peak (ZT 14, Fig. 8C) and trough (ZT 2) of
expression using IHC. There was a time-of-day difference in each
genotype as confirmed by two way ANOVA (Fig. 8D;
F1,29 = 26.27, P,0.001). At ZT 2, the trough of PER2 expression,
we found no significant effect of genotype (F2,6 = 1.774, P=0.281).
At ZT 14, the peak of PER2 expression, we also found no
significant effect of genotype (F2,11 = 0.276, P=0.765).
Our histological examination suggests that the Q175 mutation
results in no obvious effect in the SCN. There is no apparent cell
loss in the SCN at 13 months of age in the Q175 mutants. At the
level of the molecular oscillator, the Q175 mutation does not affect
the daily peak or trough of PER2 expression.
Figure 6. Motor ability of Q175 mutants declines with age. A.
The accelerating rotarod test revealed that the age-related motor
deficits in the Q175 model take up to 12 months to appear. B. 9 month
old Q175 Hom mutants take longer to traverse the challenging beam
test than age-matched WT and Q175 Het mice. C. The number of errors
made while crossing each segment of the beam are shown, with the
widest part of the beam on the left (33 mm) and narrowing towards the
right (6 mm). The beam lengths are not to scale. The number of errors
made while crossing the challenging beam are higher in Q175 Hom
mutants. * indicates P,0.05 in post hoc pairwise comparisons with WT
after an effect of genotype was detected by one way ANOVA, and ‘
indicates differences (P,0.05) between Q175 Het and Hom mice.
doi:10.1371/journal.pone.0069993.g006
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Discussion
We found age- and genotype-dependent deterioration of the
circadian parameters of activity, motor coordination and immo-
bility-defined sleep in the Q175 mutant mice. It is intriguing that
we observed greater deficits in the Q175 Hom than the Het
mutants. HD in humans is a genetically dominant condition, but
the gene dosage effect we and others [24,34] observed in the Q175
line suggests that mice are more resistant to the same genetic load
than humans. The more severe effect of a homozygous knocked-in
HD mutation on motor function has also been observed in the
CAG140 line [23] and similarly, transgenic YAC128 HD mice
Figure 7. Daytime sleep is selectively affected in Q175 mutants. A. Average waveforms of hourly sleep in WT, Q175 Het and Hom mice at 9
months (top) and 12 months of age (bottom). B. Amount of time spent in sleep in day is selectively decreased compared to night-time sleep in Q175
Hom mice at 9 (top) and 12 months of age (bottom). C. 9 (top) and 12 month (bottom) old Q175 Hom mice have more fragmented daytime sleep,
with increased number of sleep episodes. D. Sleep episodes in Q175 Hom mice are also shorter in duration. * indicates significant difference (P,0.05)
between WT and Q175 Hom mice and ‘ indicates differences (P,0.05) between Q175 Het and Hom mice.
doi:10.1371/journal.pone.0069993.g007
Figure 8. Neuron number and PER2 expression are unaffected in the SCN of Q175 mutants. A. Representative images of Nissl stains at
10X magnification of coronal sections of the SCN from WT (left), Q175 Het (middle) and Hom (right) mice. 3V: 3rd ventricle. oc: optic chiasm. B.
Quantification of Nissl+cells in the SCN from each genotype was determined by two independent observers blind to the experimental conditions. C.
SCN expression of the circadian protein, PER2, is unaltered in Q175 mutants. Mice at 12m of age were sacrificed at ZT 2 and ZT 14, the respective
trough and peak of SCN PER2 expression. Representative images of ZT 14 SCN, 40X magnification, are shown from each genotype. D. The day/night
difference in PER2 expression is unaltered in Q175 mutants. Quantification of PER2+cells in the SCN was determined by 2 independent observers
blind to the experimental conditions.
doi:10.1371/journal.pone.0069993.g008
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show a correlation between increased copy number and disease
severity [35].
The decline in the circadian parameters of activity in the Q175
Hom mice was apparent at 9 months. In particular, the power of
the rhythm under both LD and DD conditions dramatically
dropped, similar to our previous findings of reduced power of
locomotor rhythms in the BACHD model [20], albeit at a later age
in the Q175 model. While these changes were concomitant with a
decline in general locomotor activity, it is critical to note that
precision of the daily onset of activity also deteriorated at the same
time and suggests the circadian disruption is not simply due to
motor dysfunction. The decline in precision and power of rhythms
suggests an intrinsically weaker circadian oscillator, which also
manifested in a change in the temporal pattern of the activity. The
percentage of daily activity conducted in the night decreased with
age to a greater degree in the Q175 Hom than the Het and WT
mice. We observed a similar loss of temporal patterning of heart
rate and body temperature in the BACHD model, which suggests
that the circadian deficits also affect non-motor systems in HD.
It is also important to note that the Q175 Het and Hom
mutants had normal performance on the rotarod test at the same
age as the onset of the circadian deficits, suggesting that not all of
the wheel running deficits we observed could be ascribed to an
inability to turn the wheel at 9 months of age. However, by 12
months of age, Q175 Het and Hom mutants lose the motor
coordination needed to perform the rotarod test, as has been
documented in a separate cohort of Q175 mutants [24]. Further
evidence of motor deficits include an increase in errors made by
the Q175 Hom mutants while crossing the challenging beam,
which could in part be explained by decreased grip strength from
an early age [23].
In a video-based assay that is independent of the animal’s ability
to turn a wheel, we assessed the sleep behavior of the mice, and
found that daytime sleep was selectively affected by the Q175
mutation. While video analysis of sleep does not allow us to draw
conclusions regarding the depth of sleep nor the relative
progression from one state of sleep to another (e.g. NREM vs.
REM), such measurements have been shown to accurately
measure sleep and correlate highly with simultaneously recorded
EEG-defined sleep [31,36]. Using immobility-defined sleep
analysis, we found that the Q175 Hom mice spent considerably
less time asleep during the day than their WT and Het age-
matched cohort. This is reflected by the reduced nocturnality that
we observed in the wheel running assay, confirming that the
temporal patterning of activity and inactivity is aberrant in these
mutants. We also found increased fragmentation in daytime sleep
in the Q175 Hom mice, which had an increased number of sleep
bouts coupled with shorter sleep bouts than Het and WT mice at
both 9 and 12 months of age. This fragmentation is in common
with the sleep disturbances observed in HD patients, who suffer
from reduced nighttime sleep efficiency (e.g. [12]).
The aberrant circadian locomotor activity and reduced daytime
sleep that we observe suggest that an upstream regulator of
behavior is affected, and the SCN as the master pacemaker is the
most likely suspect. The SCN is dependent on intrinsic molecular
oscillators within each cell that are governed by a core set of genes
in a transcription-translation-post-translational feedback loop that
takes ,24 hr to complete each cycle (reviewed in [37]).
Examination of the rhythms of PER2 expression in the SCN
suggests that the deficit does not lie in the molecular oscillator
within the SCN, although other components of the oscillator may
be affected. However, an intact molecular oscillator in the SCN
may not be indicative of a normally functioning circadian system.
We have now consistently seen a dissociation between normal
PER2 rhythms in the SCN and reduced SCN output in three
different models of neurodegeneration: the BACHD mouse model,
a mouse model of Parkinson’s Disease, and in middle-aged mice
[20,38,39]. In the R6/2 model, the HD mutation had a stronger
impact on the non-SCN circadian oscillators, suggesting the
output mechanisms by which the SCN communicates are affected
[10,40,41].
Likely candidates for the decline in circadian output from the
SCN include deficits in neuron-to-neuron communication. For
example, neuropeptides critical for communication within the
circadian circuitry are selectively lost in the SCN of HD patients
[42]. Prior work has also demonstrated a loss of one of those
peptides, vasoactive intestinal peptide (VIP), in the SCN neurons
of the R6/2 model [43]. VIP has been shown to be critical for
robust rhythms within the SCN and for its output [25,44–46]. A
reduction in VIP would result in a weakened SCN output, and is
consistent with the circadian phenotype that we observed in the
BACHD and now in the Q175 model.
Steps towards stabilizing rhythms in the R6/2 mouse model,
e.g. scheduling meal times and imposing sleep during the day,
suggest that there is merit in pursuing treatment strategies for the
non-motor symptoms of HD, even to the extent of delaying the
progression of motor dysfunction and improving cognitive
function [40,41,47]. It is thus critical to determine the relative
contributions of disrupted rhythms versus neurodegeneration in
the motor control system on cognitive, psychiatric and metabolic
dysfunction, which would suggest better targets for therapy. The
Q175 model is a particularly salient model to study due to the
precise insertion of HD mutation into the mouse Htt locus and the
relatively similar progression of symptoms to HD patients [24,34].
The sleep and circadian rhythm disruptions observed in the Q175
line make it a promising model in which to determine how the
genetic cause of HD leads to disrupted rhythms.
Supporting Information
Figure S1 Comparison of immobility-defined sleep at
different thresholds of immobility detection. A. Amount
of sleep during the day and night in 12 month old WT, Q175 Het
and Q175 Hom mice under the three different immobility
detection thresholds. At all three detection thresholds, the Q175
Hom mice exhibit reduced daytime sleep compared to WT mice (*
P,0.05 vs. WT, ‘ P,0.05 vs. Het). B. Average sleep waveforms
do not change in shape or direction of difference under the three
different immobility thresholds.
(TIF)
Figure S2 Distribution of daytime sleep bout duration
is altered inQ175 Hom mice. A. Sleep bouts of 30 min
intervals were normalized to the total number of bouts in the day.
Short bouts of under 30 min duration were increased, and longer
bouts were decreased in Q175 Hom mice (* P,0.05 vs. WT, ‘
P,0.05 vs. Het). B. Higher resolution display of the distribution
of sleep bout durations shorter than 30 min, normalized to the
total number of bouts during the day.
(TIF)
Table S1 Comparison of immobility-defined sleep at
three thresholds of immobility detection: 90, 95 and
97%. The differences in sleep measured at the 90% and 97%
immobility detection settings compared to sleep at the 95% setting
are reported as a percentage (D). The effect of genotype was
determined using one-way ANOVA, and the F and P statistics are
reported for genotype comparisons. * indicates that post hoc
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Bonferroni’s t-tests detected significant differences compared to
WT and # indicates differences between Het and Hom.
(DOCX)
Text S1 Sleep and circadian deficits in the Q175 HD
model - Supplemental Materials.
(DOCX)
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